Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2001

View Archived Issues

Investigational immunotherapy for Alzheimer's disease enters phase IIa

Diversa and IntraBiotics discontinue antimicrobial alliance

Cell Matrix awarded grants for development of novel antiangiogenesis products

Adaptive Screening offers new approach to drug discovery

Second-quarter development progress reported by Sepracor

JNK inhibitor appears to have disease-modifying activity in rheumatoid arthritis

Role of dipeptidyl-peptidase IV in GIP metabolism, biological activity

FDA advisory committee to review IntraDose

Corvas provides status report for rNAPc2

Pilot studies suggest that EPA may be a novel therapeutic option in schizophrenia

Neurocrine Biosciences and GSK establish collaboration for CRF receptor antagonists

QLT and Novartis Ophthalmics expand verteporfin codevelopment agreement

Methotrexate-albumin conjugate may be particularly useful against prostate cancer, sarcomas

ProChon and MorphoSys identify new class of antibody

Chlamydia candidate vaccine reveals potential to protect against STD-related infertility

Inhibitors of HIV fusion and entry a focus of interest at recent conference

Abgenix and CuraGen make progress in development of novel antibody drug targets

Survival prolonged in tumor-bearing mice treated with GTI-2040

Lovastatin reduces coronary event risk in subjects with elevated C-reactive protein levels

Use of BTK inhibitor LFM-A13 for inhibiting platelet aggregation

New antitumor compounds in development at Pharmacia

Abbott claims ketolide antibacterial agents in recent patent

Preparation of dihydroquinoline derivatives and use as analgesics

Heterocyclic compounds from Takeda may have therapeutic potential in diabetic neuropathy

Antifungal chromone derivatives reported by Toyama

Kyorin's new PPAR activators reportedly useful in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...